How to Get Tresiba in Louisiana

What Is Tresiba and Why Do Louisiana Patients Request It

Tresiba is the brand name for insulin degludec, a long-acting basal insulin with an ultra-long duration of action exceeding 42 hours in most adults. The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, with a pediatric indication added later for patients as young as one year old. Novo Nordisk manufactures it in two concentrations: U-100 (100 units/mL) and U-200 (200 units/mL).

The clinical interest in insulin degludec centers on its flat, stable pharmacokinetic profile. Because the drug forms soluble multihexamer chains after subcutaneous injection, it releases insulin monomers slowly and predictably over more than 40 hours. Research published in Diabetes Care confirmed this extended half-life, which translates to a lower day-to-day variability in fasting blood glucose compared with insulin glargine U-100.

Louisiana has approximately 578,000 adults living with diagnosed diabetes according to CDC state-level estimates, representing roughly 14.5% of the adult population. That rate exceeds the national average of 11.6%, which means the demand for effective basal insulin options, including Tresiba, is proportionally high in this state.

The American Diabetes Association 2024 Standards of Care recommend individualized selection of basal insulin based on hypoglycemia risk, dosing flexibility, and cost. For patients who experience nocturnal hypoglycemia on insulin glargine or NPH, switching to insulin degludec is a supported clinical option under those guidelines.

The Prescribing Process in Louisiana: Step by Step

Getting a Tresiba prescription in Louisiana follows a clear sequence. You need a licensed Louisiana prescriber, a qualifying diagnosis, and either insurance coverage or a self-pay strategy.

Step 1: Choose your prescriber type. In Louisiana, MDs, DOs, nurse practitioners (NPs) with a collaborative practice agreement, and physician assistants (PAs) under supervising physician oversight can all prescribe insulin degludec. The Louisiana State Board of Medical Examiners governs MD and DO prescribing authority. The Louisiana State Board of Nursing governs NP prescribing. Louisiana NPs cannot prescribe Schedule II controlled substances independently, but insulin is not a controlled substance, so an NP can prescribe Tresiba under a collaborative practice agreement without a co-signature on each prescription.

Step 2: Establish a clinical encounter. A prescriber must document a diagnosis of type 1 or type 2 diabetes (ICD-10: E10.x or E11.x) and a clinical rationale for basal insulin. Labs that support this include a fasting plasma glucose, hemoglobin A1c, and a C-peptide level if type classification is uncertain. The ADA diagnostic criteria define diabetes as an A1c at or above 6.5%, fasting glucose at or above 126 mg/dL, or a 2-hour glucose at or above 200 mg/dL during an oral glucose tolerance test.

Step 3: Handle prior authorization if applicable. Most commercial plans in Louisiana place Tresiba on Tier 3 or Tier 4 of their formulary. Louisiana Medicaid (Healthy Louisiana) does not currently cover insulin degludec, so Medicaid patients must either pursue a formulary exception or use the manufacturer savings program. For commercial plans, prior authorization documentation typically requires a current A1c result, evidence of trial and failure or contraindication on a Tier 1 or Tier 2 basal insulin (usually insulin glargine or detemir), and the prescriber's clinical rationale.

Step 4: Send the prescription to a Louisiana pharmacy. Tresiba is available at most major chain pharmacies including CVS, Walgreens, and Walmart, as well as independent pharmacies across the state. The prescription may also be sent to a mail-order pharmacy or a licensed 503A compounding pharmacy if a non-standard formulation is clinically indicated.

Telehealth Prescribing for Tresiba in Louisiana

Louisiana permits synchronous telehealth visits for prescription of non-controlled medications, including insulin. A licensed Louisiana prescriber conducting a real-time audio-video visit may prescribe Tresiba without an in-person examination, provided the standard of care for evaluation and diagnosis is met.

The Louisiana Department of Health telehealth policy confirms that Medicaid-enrolled providers may bill for telemedicine services, and Louisiana commercial insurers are required under state law to reimburse telehealth services at parity with in-person visits for covered services. That parity rule does not extend to Medicaid drug coverage, so the lack of Tresiba on the Medicaid formulary remains a barrier regardless of visit modality.

A telehealth visit for Tresiba typically takes 20 to 40 minutes. The prescriber reviews your diabetes history, recent labs, current medications, and any prior hypoglycemia events. If you have A1c results or a continuous glucose monitor report from the past 90 days, uploading those before the visit speeds the process considerably. Most telehealth platforms operating in Louisiana can send a prescription electronically to your preferred pharmacy on the same day.

Patients transferring care from another state should note that a prescriber must be licensed in Louisiana to prescribe to a Louisiana address. Out-of-state prescriptions are valid for dispensing at Louisiana pharmacies only if the prescribing provider holds licensure in the state where the patient was located at the time of the visit, per DEA and state board standards. For a new telehealth prescription originating in Louisiana, the provider must hold a Louisiana license.

What Labs Are Required Before Starting Tresiba

No single mandatory lab panel is required by the FDA label, but clinical best practice and most insurance prior authorization forms ask for specific results. The ADA Standards of Care Section 6 recommend checking A1c every three months until at goal, then every six months. Before initiating any basal insulin, most endocrinologists order:

• Hemoglobin A1c (within the past 90 days for PA purposes)
• Fasting plasma glucose
• Comprehensive metabolic panel (CMP) to assess renal function, since dosing adjustments may be needed in CKD
• Thyroid-stimulating hormone (TSH) if not checked in the past 12 months, because thyroid dysfunction affects insulin sensitivity
• C-peptide and anti-glutamic acid decarboxylase (anti-GAD) antibodies if type classification is uncertain

Renal impairment does not require a formal dose reduction per the Tresiba prescribing information, but the FDA label for insulin degludec notes that patients with renal impairment may require more frequent glucose monitoring and potential dose adjustments. Creatinine and eGFR values inform that decision.

The entire lab panel can typically be ordered during the same telehealth visit. Results are usually returned within 24 to 48 hours at most commercial labs including Quest Diagnostics and LabCorp, both of which have collection sites throughout Louisiana.

The Clinical Evidence Behind Insulin Degludec

Tresiba's safety and efficacy profile rests on a substantial evidence base. The most cited cardiovascular outcomes trial is DEVOTE, a randomized, double-blind, event-driven trial that enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk. Published in the New England Journal of Medicine in 2017, DEVOTE showed that insulin degludec was non-inferior to insulin glargine U-100 for the primary composite outcome of major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (hazard ratio 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority).

Hypoglycemia outcomes in DEVOTE were particularly notable. Severe hypoglycemia rates were 40% lower with insulin degludec compared to insulin glargine U-100 (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001). Nocturnal confirmed hypoglycemia was 53% lower. These findings directly support using insulin degludec in patients who have experienced recurrent severe or nocturnal hypoglycemia on other basal insulins.

The BEGIN trial program provided efficacy data across both type 1 and type 2 diabetes. BEGIN BASAL published in Diabetologia showed that insulin degludec achieved comparable A1c reductions to insulin glargine U-100 in type 2 diabetes with significantly fewer confirmed nocturnal hypoglycemic episodes (rate ratio 0.68; P<0.001). In the BEGIN ONCE LONG trial in type 1 diabetes, insulin degludec produced non-inferior A1c reduction with a 25% lower rate of nocturnal hypoglycemia compared to insulin glargine (P<0.001).

The Endocrine Society Clinical Practice Guideline on diabetes pharmacotherapy recommends considering a switch to insulin degludec or glargine U-300 in patients experiencing recurrent hypoglycemia on first-generation basal insulins, citing the DEVOTE and BEGIN trial data as the basis.

As Dr. Steven Nissen, who chaired the DEVOTE steering committee, stated in the original NEJM publication: "The results provide reassurance regarding cardiovascular safety and demonstrate a clinically meaningful reduction in hypoglycemia that could meaningfully affect quality of life for patients with type 2 diabetes at high cardiovascular risk."

Insurance Coverage and Costs in Louisiana

Louisiana Medicaid (Healthy Louisiana) does not cover insulin degludec. Patients on Medicaid should ask their prescriber about formulary exceptions or request a transition to insulin glargine U-300 (Toujeo), which may have different formulary status.

For commercially insured patients, coverage varies by plan. Tresiba typically sits on Tier 3 of most Louisiana Blue Cross Blue Shield, Humana, and Aetna formularies, with prior authorization required. The Novo Nordisk Tresiba savings card can reduce the monthly out-of-pocket cost to as low as $99 for eligible commercially insured patients. Uninsured patients can access the Novo Nordisk Patient Assistance Program, which provides Tresiba at no cost to qualifying low-income patients.

The Endocrine Society position statement on insulin access notes that out-of-pocket insulin costs remain a major adherence barrier in the United States, particularly in Southern states with higher rates of uninsured patients.

Generic or biosimilar insulin degludec is not yet approved in the United States as of the date of this article. The FDA biosimilars database lists no approved biosimilar for insulin degludec at this time.

503A Compounding Pharmacies in Louisiana

A 503A compounding pharmacy in Louisiana can prepare insulin degludec formulations for patients with specific clinical needs, such as an unusual concentration or a formulation without a particular excipient. The FDA's 503A framework requires a valid patient-specific prescription and limits these preparations to non-commercially available variations.

Louisiana-licensed 503A pharmacies are regulated by the Louisiana Board of Pharmacy and must comply with USP <797> sterile compounding standards for any injectable preparation. Compounded insulin degludec is not substitutable for the FDA-approved commercial product and is intended for patients with documented medical necessity for the compounded formulation. Shipping to a Louisiana address from an out-of-state 503A pharmacy is permitted if the out-of-state pharmacy holds a Louisiana non-resident pharmacy permit.

Patients should verify permit status directly with the Louisiana Board of Pharmacy before ordering from an out-of-state compounding pharmacy.

How to Transfer an Existing Tresiba Prescription to Louisiana

Transferring an existing Tresiba prescription to Louisiana depends on whether the original prescription has remaining refills and whether the original prescriber is licensed in Louisiana.

If the original prescriber is not Louisiana-licensed, a new prescription from a Louisiana-licensed provider is required. The new prescriber can request your prior records, recent labs, and dosing history, and can issue an identical prescription after a brief telehealth encounter. Most platforms complete this in under 30 minutes if your records are available.

For pharmacy transfers: Louisiana pharmacies can accept an original prescription transfer from an out-of-state pharmacy for a non-controlled substance. The receiving pharmacist contacts the original dispensing pharmacy to verify remaining refills and transfers the prescription. The Louisiana Board of Pharmacy rules on prescription transfers allow one transfer per prescription for non-controlled substances at retail pharmacies. Mail-order pharmacies operate under the same rule.

The entire transfer process, from telehealth visit to pharmacy pickup, takes 24 to 72 hours in most Louisiana markets. Rural areas served by mail-order pharmacy may require an additional two to three business days for shipping.

Dosing and Administration Basics

Tresiba is injected subcutaneously once daily at any time of day. The flexible dosing window, which can shift by up to 8 hours from one day to the next without loss of glycemic control, is one of its practical advantages for patients with irregular schedules. The FDA-approved prescribing information states the minimum interval between doses is 8 hours.

Starting doses recommended in the label are:

• Insulin-naive type 2 diabetes: 10 units once daily, titrated based on fasting plasma glucose
• Type 2 diabetes converting from another basal insulin: unit-for-unit conversion from the prior basal dose, then titrate
• Type 1 diabetes: the basal portion of a basal-bolus regimen, typically two-thirds of total daily insulin, with the remainder as a rapid-acting insulin at meals

Injection sites include the abdomen, thigh, and upper arm. Rotation within and between sites reduces the risk of lipohypertrophy. ADA injection technique guidance recommends a 4 mm pen needle for most adults regardless of BMI.

Tresiba FlexTouch pens are prefilled and dose in 1-unit increments for the U-100 formulation and 2-unit increments for U-200. The U-200 pen delivers up to 160 units per injection, making it suitable for patients requiring high doses.

Managing Prior Authorization in Louisiana

Prior authorization (PA) for Tresiba follows a standard pattern across Louisiana commercial payers. The prescriber submits a PA request through the insurer's online portal or by fax. The typical documentation package includes:

• Current A1c result (dated within 90 days)
• Diagnosis code (E10.x for type 1 or E11.x for type 2 diabetes)
• Documentation of prior trial of at least one Tier 1 or Tier 2 basal insulin (insulin glargine, detemir, or NPH) and the clinical reason it is inadequate, such as recurrent hypoglycemia episodes
• Letter of medical necessity from the prescriber

PA decisions are typically returned within 24 to 72 hours for standard requests. Louisiana insurance regulations require insurers to respond to non-urgent PA requests within 72 hours and urgent requests within 24 hours, per Louisiana Department of Insurance standards.

If the initial PA is denied, the prescriber can file a peer-to-peer review request, typically by calling the insurer's medical director line within 10 business days of denial. Citing the DEVOTE severe hypoglycemia data (40% risk reduction, rate ratio 0.60) is often effective in these calls, particularly for patients with documented hypoglycemia unawareness or a history of severe hypoglycemia requiring assistance.

The American Diabetes Association's position statement on prior authorization states: "Delays in medication access due to prior authorization requirements can lead to suboptimal glycemic control, increased hospitalizations, and patient harm."